Just two months after raising $84 million from an upsized IPO, Concert Pharmaceuticals says that a key Phase II study of its lead drug–CTP-499–flopped on its primary endpoint for diabetic kidney disease. …read more Source: On heels of an IPO, Concert’s kidney drug flops in PhII
Merck is looking to Lexington, MA-based Agenus to give the pharma giant an edge in the race to develop new immuno-oncology drugs. …read more Source: Merck turns to tiny Agenus in hunt for new immunotherapies
Kite Pharma says it has raised a whopping $50 million from a group of private investors to back its work on new T cell treatments for cancer. …read more Source: Immuno-oncology specialist Kite adds $50M in new financing
Shares of OncoGenex went into meltdown mode this morning after the biotech and its partner Teva put out word that their experimental prostate cancer drug had flunked a long-awaited Phase III study. Shares of OncoGenex immediately shed more than half their value in the reckoning with investors. …read more Source: OncoGenex, Teva flag a failed […]
Furiex has landed its big buyout deal. After Furiex nabbed promising late-stage data on a new drug for irritable bowel syndrome and virtually slapping a “for sale” sign on the company, Forest Labs has swooped in to buy the biotech company for $1.1 billion and potentially $360 million in contingent value rights. …read more Source: […]
Biogen Idec has struck up a far-reaching agreement with CRO giant Quintiles, tapping the contractor to help design, plan and run its Phase II-IV studies. …read more Source: Biogen brings Quintiles to the R&D table in 5-year pact
After shifting its focus from antisense therapies to immuno-oncology last year, Germany’s Isarna Therapeutics has pulled down $7.6 million to jump-start the development of some preclinical cancer candidates. …read more Source: Isarna snags another $7.6M to advance its cancer immunotherapy
…read more Source: Actavis global R&D president departs to helm Impax Labs
Radius Health is betting the promise of its bone-boosting drug will sway investors to buy into its planned $92 million IPO, forging ahead in what has become a shaky market for biotech debuts. …read more Source: Radius dials up a $92M IPO pitch despite tepid market for biotechs
Before it started getting unwanted attention from the takeout artists at Valeant, Allergan made buyout overtures of its own to Shire, Reuters reports, getting little interest from the Irish drugmaker. …read more Source: Buyout buzz: Allergan made a pass at Shire before Valeant came calling
